Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma

被引:11
作者
Ghedira, Donia [1 ,2 ]
Voissiere, Aurelien [1 ]
Peyrode, Caroline [1 ]
Kraiem, Jamil [2 ]
Gerard, Yvain [1 ]
Maubert, Elise [1 ]
Vivier, Magali [1 ]
Miot-Noirault, Elisabeth [1 ]
Chezal, Jean-Michel [1 ]
Farhat, Farhat [2 ]
Weber, Valerie [1 ]
机构
[1] Univ Clermont Auvergne, INSERM, Imagerie Mol & Strategies Theranost U1240, F-63000 Clermont Ferrand, France
[2] Univ Monastir, Fac Pharm Monastir, Lab Dev Chim Galen & Pharmacol Medicaments, Monastir 5000, Tunisia
关键词
Hypoxia-activated prodrug; Quaternary ammonium; Chondrosarcoma; Proteoglycan; BIOLOGICAL EVALUATION; EVOFOSFAMIDE; DERIVATIVES; RESISTANCE; DESIGN; IDENTIFICATION; RESONANCE; TUMORS;
D O I
10.1016/j.ejmech.2018.08.060
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Due to an abundant chondrogenic, poorly vascularized and particularly hypoxic extracellular matrix, chondrosarcoma, a malignant cartilaginous tumour, is chemo- and radio-resistant. Surgical resection with wide margins remains the mainstay of treatment. To address the lack of therapy, our strategy aims to increase anticancer drugs targeting and delivery in the tumour, by leveraging specific chondrosarcoma hallmarks: an extensive cartilaginous extracellular matrix, namely the high negative fixed charge density and severe chronic hypoxia. A dual targeted therapy for chondrosarcoma was investigated by conjugation of a hypoxia-activated prodrug (HAP) to quaternary ammonium (QA) functions which exhibit a high affinity for polyanionic sites of proteoglycans (PGs), the major components of the chondrosarcoma extracellular matrix. Based on preclinical results, an imidazole prodrug, ICF05016, was identified and provided the basis for a lead optimization study. A series of 27 QA-phosphoramide mustard conjugates, differing by the type of QA function and the length of the alkyl linker, was yielded by a common multistep sequence involving phosphorylation of a key 2-nitroimidazole alcohol. Then, a screening was realized by surface plasmon resonance technology to assess biomolecular interactions between QA derivatives and aggrecan, the most abundant PG in chondrosarcoma. Results revealed that affinity depends more on the type of QA function, than on the linker length. Moreover, the presence of a benzyl group enhanced affinity to aggrecan. Twelve compounds were shortlisted and evaluated for antiproliferative activity (i.e., growth inhibiting concentration 50), under normoxic and hypoxic conditions using the human extraskeletal myeloid chondrosarcoma cell line (HEMC-SS). For all prodrugs, hypoxic selectivity was maintained and even increased, compared with the lead. From this study, compound 31f emerged as the most effective PG-targeted HAPs with a dissociation constant of 2.10 mu M in the SPR experiment, a hypoxia cytotoxicity ratio of 24 and an efficient reductive cleavage under chemical and enzymatic conditions. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:51 / 67
页数:17
相关论文
共 52 条
[1]   Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy [J].
Baran, Natalia ;
Konopleva, Marina .
CLINICAL CANCER RESEARCH, 2017, 23 (10) :2382-2390
[2]   Long-term Outcome of Chondrosarcoma: A Single Institutional Experience [J].
Bindiganavile, Srimanth ;
Han, Ilkyu ;
Yun, Ji Yeon ;
Kim, Han-Soo .
CANCER RESEARCH AND TREATMENT, 2015, 47 (04) :897-903
[3]   SYNTHESIS AND ANTITUMOR PROPERTIES OF ACTIVATED CYCLOPHOSPHAMIDE ANALOGS [J].
BORCH, RF ;
CANUTE, GW .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (10) :3044-3052
[4]   Cartilage tumours and bone development: molecular pathology and possible therapeutic targets [J].
Bovee, Judith V. M. G. ;
Hogendoorn, Pancras C. W. ;
Wunder, Jay S. ;
Alman, Benjamin A. .
NATURE REVIEWS CANCER, 2010, 10 (07) :481-488
[5]   Exploiting tumour hypoxia in cancer treatment [J].
Brown, JM ;
William, WR .
NATURE REVIEWS CANCER, 2004, 4 (06) :437-447
[6]   Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Casali, Paolo G. ;
Blay, Jean-Yves ;
Bertuzzi, Alexia ;
Bielack, Stefan ;
Bjerkehagen, Bodil ;
Bonvalot, Sylvie ;
Boukovinas, Ioannis ;
Bruzzi, Paolo ;
Dei Tos, Angelo Paolo ;
Dileo, Palma ;
Eriksson, Mikael ;
Fedenko, Alexander ;
Ferrari, Andrea ;
Ferrari, Stefano ;
Gelderblom, Hans ;
Grimer, Robert ;
Gronchi, Alessandro ;
Haas, Rick ;
Hall, Kirsten Sundby ;
Hohenberger, Peter ;
Issels, Rolf ;
Joensuu, Heikki ;
Judson, Ian ;
Le Cesne, Axel ;
Litiere, Saskia ;
Martin-Broto, Javier ;
Merimsky, Ofer ;
Montemurro, Michael ;
Morosi, Carlo ;
Picci, Piero ;
Ray-Coquard, Isabelle ;
Reichardt, Peter ;
Rutkowski, Piotr ;
Schlemmer, Marcus ;
Stacchiotti, Silvia ;
Torri, Valter ;
Trama, Annalisa ;
Van Coevorden, Frits ;
Van der Graaf, Winette ;
Vanel, Daniel ;
Wardelmann, Eva .
ANNALS OF ONCOLOGY, 2014, 25 :113-123
[7]   SYNTHESIS OF 1-ALKYL-2-NITROIMIDAZOLE-5-CARBOXALDEHYDES [J].
CAVALLERI, B ;
BALLOTTA, R ;
LANCINI, GC .
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1972, 9 (05) :979-+
[8]   Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box [J].
Celik, Haydar ;
Hong, Sung-Hyeok ;
Colon-Lopez, Daisy D. ;
Han, Jenny ;
Kont, Yasemin Saygideger ;
Minas, Tsion Z. ;
Swift, Matthew ;
Paige, Mikell ;
Glasgow, Eric ;
Toretsky, Jeffrey A. ;
Bosch, Juergen ;
Ueren, Aykut .
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (11) :2497-2507
[9]   New horizons in tumor microenvironment biology: challenges and opportunities [J].
Chen, Fei ;
Zhuang, Xueqian ;
Lin, Liangyu ;
Yu, Pengfei ;
Wang, Ying ;
Shi, Yufang ;
Hu, Guohong ;
Sun, Yu .
BMC MEDICINE, 2015, 13
[10]  
David E, 2011, SARCOMA, V2011